REGENXBIO Inc. (RGNX) Reaches $50.55 After 9.00% Up Move; Loxo Oncology (LOXO)’s Sentiment Is 0.97

May 15, 2018 - By Hazel Jackson

Loxo Oncology, Inc. (NASDAQ:LOXO) Logo

The stock of REGENXBIO Inc. (NASDAQ:RGNX) is a huge mover today! The stock increased 2.22% or $1.1 during the last trading session, reaching $50.55. About 328,695 shares traded. REGENXBIO Inc. (NASDAQ:RGNX) has risen 43.49% since May 15, 2017 and is uptrending. It has outperformed by 31.94% the S&P500.The move comes after 8 months positive chart setup for the $1.61B company. It was reported on May, 15 by Barchart.com. We have $55.10 PT which if reached, will make NASDAQ:RGNX worth $145.26M more.

Loxo Oncology (LOXO) investors sentiment decreased to 0.97 in Q4 2017. It’s down -0.76, from 1.73 in 2017Q3. The ratio has dropped, as 70 institutional investors increased or started new positions, while 72 reduced and sold positions in Loxo Oncology. The institutional investors in our database now own: 124.82 million shares, up from 29.06 million shares in 2017Q3. Also, the number of institutional investors holding Loxo Oncology in top ten positions decreased from 6 to 5 for a decrease of 1. Sold All: 29 Reduced: 43 Increased: 47 New Position: 23.

Analysts await REGENXBIO Inc. (NASDAQ:RGNX) to report earnings on August, 14. They expect $1.90 earnings per share, up 504.26% or $2.37 from last year’s $-0.47 per share. RGNX’s profit will be $60.66M for 6.65 P/E if the $1.90 EPS becomes a reality. After $3.00 actual earnings per share reported by REGENXBIO Inc. for the previous quarter, Wall Street now forecasts -36.67% negative EPS growth.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. The company has market cap of $1.61 billion. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. It currently has negative earnings. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.

Among 4 analysts covering Regenxbio (NASDAQ:RGNX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Regenxbio has $33 highest and $29 lowest target. $31’s average target is -38.67% below currents $50.55 stock price. Regenxbio had 4 analyst reports since October 12, 2015 according to SRatingsIntel. The stock of REGENXBIO Inc. (NASDAQ:RGNX) earned “Buy” rating by Bank of America on Monday, October 12. The company was initiated on Monday, October 12 by Piper Jaffray. The stock of REGENXBIO Inc. (NASDAQ:RGNX) earned “Buy” rating by Chardan Capital Markets on Tuesday, October 20. The firm earned “Overweight” rating on Tuesday, October 13 by Morgan Stanley.

More notable recent REGENXBIO Inc. (NASDAQ:RGNX) news were published by: Seekingalpha.com which released: “REGENXBIO’s (RGNX) CEO Ken Mills on Q1 2018 Results – Earnings Call Transcript” on May 12, 2018, also Seekingalpha.com with their article: “REGENXBIO: An Underappreciated Leader In Gene Editing” published on April 21, 2018, Seekingalpha.com published: “Genomic Medicine: Catch The Gene Therapy Wave” on May 14, 2018. More interesting news about REGENXBIO Inc. (NASDAQ:RGNX) were released by: Prnewswire.com and their article: “REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation” published on May 15, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” with publication date: May 11, 2018.

Since January 1, 0001, it had 0 buys, and 20 selling transactions for $73.97 million activity.

More notable recent Loxo Oncology, Inc. (NASDAQ:LOXO) news were published by: Nasdaq.com which released: “Loxo Oncology Reports First Quarter 2018 Financial Results” on May 08, 2018, also Globenewswire.com with their article: “Loxo Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)” published on May 07, 2018, Globenewswire.com published: “Loxo Oncology to Announce First Quarter 2018 Financial Results” on May 01, 2018. More interesting news about Loxo Oncology, Inc. (NASDAQ:LOXO) were released by: Benzinga.com and their article: “Morgan Stanley Upgrades Loxo On The Potential Of A Targeted Cancer Therapy” published on April 16, 2018 as well as Seekingalpha.com‘s news article titled: “Loxo Oncology’s (LOXO) CEO Josh Bilenker on Q1 2018 Results – Earnings Call Transcript” with publication date: May 08, 2018.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $4.16 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

The stock increased 1.77% or $2.41 during the last trading session, reaching $138.37. About 271,034 shares traded. Loxo Oncology, Inc. (LOXO) has risen 146.80% since May 15, 2017 and is uptrending. It has outperformed by 135.25% the S&P500.

Aisling Capital Llc holds 57.19% of its portfolio in Loxo Oncology, Inc. for 3.44 million shares. Dafna Capital Management Llc owns 296,000 shares or 13.42% of their US portfolio. Moreover, Opaleye Management Inc. has 4.75% invested in the company for 176,300 shares. The Illinois-based Driehaus Capital Management Llc has invested 1.83% in the stock. Sectoral Asset Management Inc, a Quebec – Canada-based fund reported 152,185 shares.

Loxo Oncology, Inc. (NASDAQ:LOXO) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>